cbdMD, Inc. (YCBD) 股票分析

公司概述

cbdMD, Inc. (NYSE: YCBD) operates as a producer and distributor of various cannabidiol (CBD) products across the United States and international markets, maintaining ownership and operation of multiple consumer hemp-based CBD brands. The company's product portfolio encompasses oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived items, positioning it within the broader healthcare ecosystem. Specifically, the firm is classified in the Healthcare sector and functions within the Drug Manufacturers - Specialty & Generic industry, a classification that highlights its focus on specialized therapeutic compounds and generic formulations rather than big pharmaceuticals. In terms of scale, the entity reports a market capitalization of $7.35M, annual revenue of $19.09M, and employs 42 individuals. These valuation and revenue figures indicate a small-cap status, suggesting the company operates with a limited resource base and serves a niche market segment where the total addressable market is still developing relative to larger pharmaceutical peers.

财务健康

The company reported revenue of $19.09M for the trailing twelve months, yet this top-line figure masks a significant operational challenge as the net income stands at -$3,714,599, revealing a cost structure where expenses substantially exceed gross profits. The EBITDA figure of -$1,289,030 further underscores the difficulty in covering fixed costs and operational overheads before interest and tax implications. Free cash flow is reported at -$6,108,247, which indicates a severe lack of financial flexibility, as the company is burning cash faster than it can generate from operations, necessitating reliance on existing liquidity or external financing. Analyzing the margins shows a gross margin of 60.6%, which reflects strong pricing power or high-margin product mix on a unit basis, yet this is eroded by an operating margin of -5.7% and a profit margin of -12.3%, indicating that operating expenses and general administrative costs are consuming the majority of the gross profit. Regarding capital structure, the company holds $3.39M in cash against $593,026 in debt, resulting in a debt-to-equity ratio of 6.58, which suggests a highly leveraged position relative to its equity base despite the absolute dollar amount of debt being low. The current ratio is 2.94, indicating that the company possesses sufficient short-term liquid assets to cover its short-term liabilities nearly three times over, providing a buffer against immediate liquidity crises. Furthermore, the return on equity is -43.4% and the return on assets is -12.7%, metrics that reveal management is currently generating negative returns on the capital invested and the assets utilized, signaling inefficiency in deploying resources to generate shareholder value.

估值评估

The trailing P/E ratio is 1.17, while the forward P/E is -0.79, a divergence that implies the market expects earnings to remain negative or deteriorate further in the near future rather than an immediate rebound. The price-to-book ratio is 0.78, indicating that the stock is trading at a discount to its book value, which often reflects market skepticism regarding the quality of assets or the ability to convert them into cash flow. Alternative valuation metrics such as the price-to-sales ratio of 0.38 and an EV/EBITDA of -3.53 suggest that the company is valued based on sales multiples due to the absence of earnings, highlighting the speculative nature of the investment. The 52-week high is $2.56 and the 52-week low is $0.47, meaning the current market price sits somewhere within this volatile range, reflecting significant uncertainty about the stock's intrinsic value. The beta value is 2.10, which indicates that the stock price is more than twice as volatile as the broader market, exposing investors to substantial price swings that amplify both potential gains and losses relative to a standard market index.

Growth & Income

The revenue growth year-over-year is -1.9%, while earnings growth is N/A due to the lack of profitability, implying that the company is contracting in terms of sales rather than expanding its market share. Since the company is a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute income to shareholders, instead retaining all earnings to attempt to fund operations or growth initiatives. The current growth profile is characterized by a contraction in revenue and a complete absence of distributable earnings, presenting a challenging income profile for income-seeking investors. Overall, the financial trajectory points to a company in a turnaround phase where capital preservation is the primary objective rather than expansion or income generation.